No Data
No Data
Express News | CorMedix Inc. Announces Outpatient Availability of Defencath
CorMedix Inc. Announces Outpatient Availability of DefenCath
BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today
CORMEDIX INC. ANNOUNCES OUTPATIENT AVAILABILITY OF DEFENCATH
July 3, 2024Berkeley Heights, NJ – July 3, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, tod
Truist Financial Initiates CorMedix(CRMD.US) With Buy Rating
Truist Financial analyst Nicole Germino initiates coverage on $CorMedix(CRMD.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 57.7% and a total average return of 67
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $10
Needham analyst Serge Belanger maintains $CorMedix(CRMD.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 41.9% and a total av
CorMedix to Start DefenCath Label Expansion Program This Year